Literature DB >> 4874220

[Pharmacology of isoxazole and pyrazole derivatives].

J Vetulani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 4874220

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw        ISSN： 0032-5449            Impact factor:   0.270


× No keyword cloud information.
  9 in total

1.  Primary central nervous system lymphomatoid granulomatosis: a case report.

Authors:  Yuanyuan Xiang; Peng Yan; Shan Li; Yuan Xue; Cuicui Liu; Jifeng Li; Qinjian Sun; Yifeng Du; Xiaohui Liu
Journal:  Neurol Sci       Date:  2020-10-20       Impact factor: 3.307

2.  Bptf determines oncogenic addiction in aggressive B-cell lymphomas.

Authors:  Irene Felipe; Pilar Delgado; Laia Richart; Mónica P de Andrés; Jaime Prieto; Natalia Del Pozo; Juan F García; Miguel A Piris; Almudena Ramiro; Francisco X Real
Journal:  Oncogene       Date:  2020-05-25       Impact factor: 9.867

Review 3.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 4.  The promise of a prophylactic Epstein-Barr virus vaccine.

Authors:  Henry H Balfour; David O Schmeling; Jennifer M Grimm-Geris
Journal:  Pediatr Res       Date:  2019-10-03       Impact factor: 3.756

5.  Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas.

Authors:  Ivonne Vazquez; Natalia Papaleo; Joan Lop; Anna Puiggros; Blanca Sanchez-Gonzalez; Ramon Diez-Feijoo; Eva Gimeno; Marcio Andrade-Campos; Antonio Salar; Blanca Espinet; Marta Salido; Gustavo Tapia; Joaquim Carreras; Ana Ferrer; Leonor Arenillas; Xavier Calvo; Luis Colomo
Journal:  Virchows Arch       Date:  2021-04-03       Impact factor: 4.064

6.  Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.

Authors:  Kouichi Ohya; Shuhei Okuyama; Shin-Ya Ogata; Kunihiko Maeda; Kyohei Yamada; Kouichi Ohshima; Katsushi Tajima
Journal:  Ann Hematol       Date:  2021-08-24       Impact factor: 3.673

7.  Characterization of the fecal microbiome in cats with inflammatory bowel disease or alimentary small cell lymphoma.

Authors:  Sina Marsilio; Rachel Pilla; Benjamin Sarawichitr; Betty Chow; Steve L Hill; Mark R Ackermann; J Scot Estep; Jonathan A Lidbury; Joerg M Steiner; Jan S Suchodolski
Journal:  Sci Rep       Date:  2019-12-16       Impact factor: 4.379

8.  Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East.

Authors:  Saad Akhtar; M Shahzad Rauf; Yasser Khafaga; Amani Al-Kofide; Tusneem Ahmed M Elhassan; Mahmoud A Elshenawy; Juzer Nadri; Ali Hassan Mushtaq; Nasir Bakshi; Mohammed Shamayel; Suleiman Al-Sweedan; Sohail Sarwar; Irfan Maghfoor
Journal:  BMC Cancer       Date:  2021-04-01       Impact factor: 4.430

9.  Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.

Authors:  Won Seog Kim; Yasuhiro Oki; Seok Jin Kim; Sang Eun Yoon; Kirit M Ardeshna; Yi Lin; Jia Ruan; Pierluigi Porcu; Jonathan E Brammer; Eric D Jacobsen; Dok Hyun Yoon; Cheolwon Suh; Felipe Suarez; John Radford; Lihua E Budde; Jin Seok Kim; Emmanuel Bachy; Hun Ju Lee; Catherine M Bollard; Arnaud Jaccard; Hye Jin Kang; Shannon Inman; Maryann Murray; Katherin E Combs; Daniel Y Lee; Ranjana Advani; Kurt C Gunter; Cliona M Rooney; Helen E Heslop
Journal:  Ann Hematol       Date:  2021-07-24       Impact factor: 3.673
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.